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a b s t r a c t
Major Depressive Disorder (MDD) is a psychiatric disorder characterized by high comorbidity with
cardiovascular disease. Furthermore, a combination of high heart rate (HR) and low heart rate variability
(HRV) has been frequently reported in depressed patients. The present review proposes a frontal-vagal
(brain-heart) network that overlaps with functional nodes of the depression network. Moreover, we
summarize neuromodulation studies that have targeted key nodes in this depression network, with
subsequent impact on heart rate (HR) or heart-rate-variability (HRV), such as the dorsolateral prefrontal
cortex (DLPFC), subgenual anterior cingulate cortex (sgACC), and the vagus nerve (VN). Based on the
interplay of this frontal-vagal network, we emphasize the importance of including HR and HRV mea-
surements in human depression studies, in particular those that conduct neuromodulation, in order to
obtain a better understanding of the pathways that are affected, and we explore the possibilities of using
this frontal-vagal interplay as a method for target engagement in neuromodulation treatments. This
frontal-vagal network theory opens-up the possibility for individualizing neuromodulation treatments
such as rTMS. A recent development called Neuro-Cardiac-Guided TMS (NCG-TMS), was developed based
on this theory, and an individual-participant meta-analysis is presented. Four studies provide consistent
and replicable support for NCG-TMS as a target engagement method, with consistent HR deceleration
during frontal TMS and HR acceleration during motor strip TMS.
© 2019 The Author(s). Published by Elsevier Inc. This is an open access article under the CC BY license
(http://creativecommons.org/licenses/by/4.0/).
Introduction
Major Depressive Disorder (MDD) is a chronic, heterogeneous
psychiatric disorder with a remitting and relapsing course. Despite
the variety of available treatments (e.g. antidepressants and psy-
chotherapy), up to 40e50% of patients fail to respond [1]. Antide-
pressant medication is considered a first-line treatment for MDD, in
particular the use of selective serotonin reuptake inhibitors (SSRI's)
and serotonin-norepinephrine reuptake inhibitors (SNRI's) [2].
New neuromodulation treatments such as repetitive Transcranial
Magnetic Stimulation (rTMS), transcranial Direct Current
Stimulation (tDCS) and Deep Brain Stimulation (DBS) show prom-
ising clinical benefit in MDD [3e7]. These new neuromodulation
treatments target key structures that are affected in depression
such as the dorsolateral prefrontal cortex (DLPFC), the dorsomedial
prefrontal cortex (DMPFC) and the subgenual cingulate cortex
(sgACC), and the vagus nerve (VN). Stimulation of these regions is
associated with symptom improvement in MDD [6,8e10]. Recent
insights into how these neuromodulation treatments work suggest
network connectivity between the DLPFC and the (sg)ACC, which
may be mediating clinical response [11,12]. The VN, part of the
parasympathetic branch of the autonomic nervous system, in-
fluences bodily functions such as heart rate (HR) and respiration,
and stimulation of the VN consistently leads to HR decelerations
[13]. Interestingly, several studies have also reported HR de-
celerations after stimulation of the DLPFC using rTMS and tDCS
[14]. It is further known that heart rate in MDD is often dysregu-
lated, expressed in overall higher HR and lower heart rate
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variability (HRV) [15e17], which has been reported to be normal-
ized after neuromodulation treatment, but not after treatment with
SSRI's [18,19]. The goal of this narrative review is to outline the
brain-heart network or frontal-vagal network and the overlap with
the depression network, as identified with neuromodulation
treatment. As an extension to this narrative review, a commentary
is provided how to use the heart-brain link to identify potential
targets for future neuromodulation interventions and to refine
target selection in neuromodulation treatments, as well as an in-
dividual participant meta-analysis demonstrating the consistency
of this effect.
An anatomical framework of the brain-heart connection
In Fig. 1 below a summary can be found outlining the neuro-
anatomical framework of the brain-heart connection. A more
elaborate review on all these specific components can be found in
the supplementary material.
Major Depressive Disorder (MDD) and the autonomic nervous
system
Previous research indicates comorbidity between cardiovascu-
lar disease andMDDwhich is a pertinent public health concern due
to the fact that both diseases are leading causes of disability
[20e22]. Several studies have shown that depression increases risk
for cardiovascular illness from two to fivefold. Moreover, autonomic
regulation is already disturbed in depressed patients without heart
disease, manifested in an overall higher HR, and lower HRV in
comparison to healthy controls [15,16,23,24], which is more pro-
nounced in patients with severe MDD [25], indicating overlap be-
tween the depression network and the heart-brain axis.
HRV is extensively studied in depressed patients and healthy
individuals (for meta-analysis, see Ref. [19]), for a general back-
ground on HRV measures see part 2.3 of the supplementary ma-
terial). Low HRV is related to maladaptive and hyper-vigilant
processing of emotional stimuli [26], which is believed to be a
right-hemispheric function. In addition, low HRV is linked to a
hypoactive prefrontal regulation and is associated with disturbed
processing of environmental changes. In contrast, higher HRV is
associated with an effective functioning of inhibitory circuits be-
tween the prefrontal cortices and the subcortical areas, and enables
flexible responses to environmental influences [27,28]. Higher HRV
is also related to an adaptive and increased top-down and bottom
up modulation of cognitive emotional processing and to effective
processing of negative stimuli [29].
Interestingly, HRV is related to several factors which are linked
to depression as well, such as circadian rhythm, seasonality, gender,
exercise and smoking [30,31]. Furthermore, dysregulated HR pat-
terns are also seen when sleep patterns are disturbed due to
misalignment of the circadian rhythm [32], and for other somatic
processes such as an increased appetite [33].
The vagus nerve projects to visceral organs and was shown to
affect appetite [34,35]. It was also shown that transcutaneous vagus
nerve stimulation improved insomnia even before improving
symptoms of depression [35], thus indicating that both appetite
and insomnia, common symptoms of MDD, are also vagally medi-
ated, though perhaps afferent instead of efferent.
Depression is found to bemore common inwomen compared to
men, in general, and HRV is lower in females as well [36]. However,
there are some mixed findings for this assertion as gender differ-
ences in HRV seem to be age and measure dependent, and age is an
important modulator of HRV [37]. Gender differences decrease
with age, starting from 30 years old, and disappear around the age
of 50, dependent onwhatmeasure for HRV is used [38]. This may be
attributed to the level of estrogen [39]. It appears that depressed
men have lower HRV levels compared to nondepressed men. Yet,
depressed women show higher HRV levels compared to nonde-
pressed women, although this finding from one study had a small
sample size [40]. Still, in another small sized study, the same trend
was found in healthy subjects when investigating HRV and daily
sadness [41], so this assertion is not settled yet. However, depressed
women seem to have higher HRV levels than depressed men [42]
and this might explain the higher mortality rates for men [43].
Other studies have found reduced vagal activity (higher LF/HF ra-
tios) and higher HR in depressed patients compared to healthy
controls, when controlling for gender in a small sample [44]. HRV
seems to fluctuate during winter/summer [31] and a peak of pa-
tients with heart failure also occurs in winter [45]. Contrary,
increased vagal tone has been found in patients with seasonal af-
fective disorder (SAD) during winter, however, the symptomology
of this disorder (weight gain, increased appetite, hypersomnia) is
different to that from depression (weight loss, decreased appetite,
insomnia) [46]. Interestingly, season of birth seems to influence
HRV later in life [47] and being born in winter seems to be car-
dioprotective [48]. In line with this, there is a higher risk for
depression when being born in spring, and this is lower in winter
[49,50]. Exercise tends to increase HRV [36], and lower HR. Several
studies suggest that exercise has a preventive action on depression
and may serve as treatment option [51]. Thus, HR and HRV is
associated withmany factors that are dysregulated in depression as
well, further suggestive of a link between the depression network
and the heart-brain axis.
A biofeedback technique called Heart Rate Variability Biofeed-
back (HRV-BF) has been shown to have anti-depressive effects,
either by itself or when combined with evidence based behavioral
treatments. During HRV-BF, patients are assessed to find a
breathing frequency that produces the maximum effect on the
vagal pacing of the heart (called respiratory sinus arrhythmia). A
recent review on the effects of HRV-BF and emotion regulation,
concludes that HR oscillations can enhance emotion by entraining
brain rhythms inways that enhance regulatory brain networks [52].
An open-label study where 11 depressed patients practiced HRV-BF
as the sole treatment, indicated that by session 4, patients with
mild depression showed improvements in sleep, hygiene, fatigue,
and concentration. In addition, after receiving HRV-BF, there was a
decrease in depression severity and an increase in HRV, after 10
sessions [53]. The effects of HRV-BF in MDD patients were also
compared to a control group, and to healthy subjects: After two
weeks of treatment HRV increased for the HRV-BF group, but not in
the active control group (relaxed rest) or in healthy subjects
receiving biofeedback. Furthermore, at follow-up, mood was
improved in depressed patients [54]. Other studies have shown
reductions in depressive symptoms in various patient groups
[55,56].
The mechanisms behind HRV-BF may parallel the pathways
implicated in VN stimulation (VNS). By using Heart Beat Evoked
Potentials (HEP), researchers discovered that perception of visceral
phenomena such as HR may be mediated by vagal afferent path-
ways [57]. MacKinnon et al. showed that the HEP (n250) responded
to paced breathing at the optimal or resonance frequency used in
HRV-BF [58]. 5 training sessions in HRV-BF vs. EMG relaxation,
greatly increased the signal to the brain from the heart, further
reinforcing this finding [59].
Thus, MDD, HR and HRV are linked to each other. Interestingly,
different neuromodulation techniques, such as VNS, TMS, and
potentially DBS, have proven to be successful and effective in
treating depression in patients, and also have subsequent effects on
cardiac measures such as HR and HRV, possibly (1) increasing
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parasympathetic activity, (2) decreasing sympathetic activity, or (3)
both.
Cardiac effects of neuromodulation on MDD treatment targets
Vagus nerve
In the treatment of severely treatment-resistant depression, the
VN has been considered a target for treatment, using Vagus Nerve
stimulation (VNS). The VN is the most direct (parasympathetic)
connection to the heart, thus during VNS HR consistently decreases
[13,60], with a maximum effect approximately within 5 s from
onset of stimulation. VNS is an invasive technique that stimulates
the left branch of the VN through electrical current [61,62],
although new noninvasive techniques to target the VN are
emerging, such as transcutaneous VNS (tVNS) [63], that also
increased HRV [64]. VNS in MDD patients has been shown to pro-
duce increases in time-domain HRV measured by RMSSD (Root
Mean Square of the Successive Differences) [65]. Animal research
indicates that VNS can affect widespread brain regions, such as the
orbital cortex, lateral frontal cortex, anterior rhinal sulcus and
amygdala [66], and influence cardiac responses [67].
VMPFC
The VMPFC includes both the rostral anterior cingulate cortex
(rACC) and the sgACC, which are subdivisions of the ACC. The sgACC
has been implicated in depression and autonomic nervous system
activity. This area is observed to be hyperactive in depressed adults
and adolescents compared to healthy individuals, observed with
positron emission tomography (PET) scans and with functional
magnetic resonance imaging (fMRI) [6,11]. The antidepressant
response after deep brain stimulation (DBS) in the sgACC is medi-
ated by the direct down regulation of this area [6]. DBS is an
invasive neuromodulatory technique that uses electrodes that need
to be placed in different subcortical nuclei through surgery.
Compared to healthy subjects, depressed patients show an altered
emotional state shifting, due to abnormal sgACC activity, which
subsequently leads to altered vagal control [68]. There have not
been many studies investigating the direct effect of deep brain
stimulation on the VMPFC in relation to HR, although it was
demonstrated in monkeys that electrical stimulation in the pre-
genual ACC was associated with cardiac slowing [69]. Furthermore,
bradycardia was observed after electrical stimulation of the rostral
cingular region in monkeys [70]. Stronger stimulation also pro-
duced increased slowing of the HR. The inhibitory effect on the
heart was accentuated and prolonged in monkeys that have
received eserine, indicating vagal activity, since eserine prevents
the break-down of acetylcholine [70]. Also in rabbits, electrical
stimulation of the medial frontal cortex led to bradycardia [71].
The studies on deep brain stimulation and HR effects in human
subjects are limited and use often different targets: the PAG, sub-
thalamic nucleus (STN), globus pallidum and hypothalamus, all
showing an increase in HR [72]. Only recently, it was shown in 7
MDD patients that deep brain stimulation of the subgenual
cingulate (SCC) white matter (which corresponds to the sgACC) was
associated with larger HR acceleration than sham stimulation, in
cases where an intraoperative behavior response was observed, but
only after left hemispheric stimulation. Thus, this study indicates
that with DBS, HR accelerates rather than decelerates after SCC
stimulation. This may be explained by the finding that across all 7
patients, there was a significant relationship between the esti-
mated structural connectivity of the left SCC VTA to the mid-
cingulate cortex and the change in HR: the greater the structural
connectivity, the more the HR increased [73]. Furthermore, it was
suggested that the SCC has greater connectivity to the dorsal
anterior cingulate which is thought to be linked to the sympathetic
system [74,75], subsequently causing HR accelerations. Another
important consideration is the true focality of DBS in these studies,
since the electrical stimulation intensity in MDD DBS studies is
often higher relative to Parkinson DBS studies, and more diffuse as
demonstrated by electrical field modelling [76]. The latter SCC DBS
study applied stimulation at 6mA [73], while for example in the
rabbit study HR decelerations were observed at 40 mA [71], and
0.5e1mA in monkeys [69]. Therefore, more human studies with
adequate stimulation parameters are needed to confirm the sgACC
to be the relay station in this frontal-vagal network.
DLPFC
rTMS is a non-invasive neuromodulation antidepressant treat-
ment which has been shown to be able to influence HR, when
aimed at the DLPFC [14]. The efficacy of rTMS in the treatment of
MDD has been well established in recent years, especially for non-
responders to conventional treatments. Currently, remission rates
to rTMS are around 37% [77], and higher when combined with
psychotherapy 56% [78]. As rTMS is limited to cortical surfaces, it is
hypothesized that DLPFC-rTMS might exert its antidepressant ef-
fect via trans-synaptic activation of deeper regions, such as the
sgACC. The sgACC could carry the signal further to deeper brain
structures and subsequently have an impact on HR via the VN. Fox
et al. (2012) demonstrated a negative correlation between BOLD
activity in the sgACC and the DLPFC which was hypothesized to be
associated to the antidepressant mechanism of rTMS [12], the
higher the anticorrelation, the better the treatment response. In
addition, DBS of the sgACC which suppresses activity, results in an
up regulation of the activity in the DLPFC [6]. It is suggested that
DLPFC-rTMS exerts its clinical effect via functional connectivity to
the sgACC, the more negative the correlation between the two
areas was, the better a patient responded to rTMS [12]. In summary,
irrespective of the direction and causality, there is an intricate
interplay between the sgACC and DLPFC, and this interplay medi-
ates antidepressant response to rTMS.
The DLPFC has been frequently selected as a target area in non-
invasive neuromodulation research such as rTMS and tDCS due to
the accessibility of this node in the depression network. For both
rTMS and tDCS, several studies have investigated the effects on HR
(for a complete overview see Ref. [14]). In short, it was found that
both tDCS and TMS reduced HR, but the cardiac effects of TMS were
stronger relative to tDCS [14]. Furthermore, prefrontal stimulation
was more effective in reducing HR relative to Motor Cortex stim-
ulation. The DLPFC is usually targeted either on the right side with
low (1 Hz) or on the left side with high frequency (10e20Hz)
stimulation. A study conducted in healthy subjects found reduced
HR after rTMS over both the left and right DLPFC and decreased
arterial pressure after left DLPFC-rTMS [79]. A study by Udupa et al.
(2007) compared the effects of 2 weeks of rTMS with 4 weeks of
SSRIs on HRV in antidepressant naïve MDD patients. This study did
not implement a sham rTMS intervention in order to control for
placebo effects, but measured HRV before and after each treatment.
No difference was found on treatment outcome (all interventions
were equally effective) and reduced sympathovagal balance was
found in both groups. An interaction effect with treatment typewas
found for SDNN, RMSSD, LF and LF/HF ratio, which indicated a
greater reduction in sympathovagal balance in the rTMS group.
However, no significant correlation between clinical improvement
and autonomic function parameters was found [80]. Another study,
using intermittent theta burst stimulation (iTBS) in 15 MDD pa-
tients, showed that within the first minute of stimulation on the
DLPFC a HR deceleration was observed that was significantly larger
T.A. Iseger et al. / Brain Stimulation 13 (2020) 1e9 3
Fig. 1. Visual overview of sympathetic and parasympathetic brain-heart connections. Anatomical and functional connections between the brain, spinal cord and the heart for the
sympathetic pathway (accelerator nerve, indicated in green) and the parasympathetic pathway (vagus nerve, indicated in blue).
AMB: nucleus ambiguus; AMY: basolateral amygdala and the central nucleus of the amygdala (CeA); CVLM: caudal ventrolateral medullary neurons; dACC: dorsal anterior cingulate
cortex; DLPFC: dorsolateral prefrontal cortex; DVMN: dorsal vagal motor nuclei; Hyp: hypothalamus (lateral and paraventricular); IML: intermediolateral cell column of the spinal
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than during sham stimulation, thereby highlighting the acute ef-
fects on HR. More importantly, this study showed a relationship
between HR deceleration in the first 30 s (difference between sham
and active) with HRSD reduction, indicating that the larger the HR
deceleration, the better treatment outcome [96].
These studies suggest that prefrontal TMS is capable of trans-
ynaptically decreasing HR, influencing HRV and possibly normal-
izing parasympathetic functioning in MDD. However, despite the
promising clinical results of targeting the DLPFC, one outstanding
problem involves identification of an individualized stimulation
location [81,82].
Target engagement
In all, because of the overlap of the hubs in the depression
network (DLPFC, sgACC, VN) with the heart-brain axis, stimulation
of these hubs consequently leads to HR decelerations. This inter-
action might offer possibilities for improving localization of the
stimulation target. As reviewed in the supplementary material, the
effect of the VN on the heart is rapid; stimulation of the VN usually
results in an immediate response of the heart, typically occurring
within the cardiac cycle in which the stimulation occurred, with a
peak in HR deceleration within 5 s (in pigs) [13]. The return to a
normal HR is very quick after the activity of the VN is reduced
[83,84], indicating that it could be verified within a few seconds
whether coil or electrode positioning is optimal, taking the time for
the signal to travel from the target location to the VN into account.
This may be used for choosing an individual optimal target for, for
example, TMS. In a proof-of-concept study, TMS was aimed to
locate the DLPFC according to HR deceleration [85]. HR data of 10
subjects was collected, while stimulating with 5 s trains of 10 Hz
TMS on various prefrontal locations (F4, FC4 and C4, F3, FC3 and C3)
according to the 10e20 system. In this study, respiration was
“filtered out” by converting the ECG to RR intervals and taking only
the troughs of this signal (see Fig. 2). The rationale for this was that
the troughs represent the highest HR and could thus show a
deceleration more clearly. In line with the hypothesis, it was found
that on the group level, the locations that led best to the largest HR
decelerations were F3 and F4, and these are conventionally used as
rTMS targets (also referred to as the Beam-F3 method). However,
individually, some subjects expressed larger HR decelerations at
FC3 or FC4, indicating individual variation. On the other hand, no
subject expressed the largest HR decelerations at C3 or C4 [85].
This method of Neuro-Cardiac-Guided TMS (NCG-TMS) has now
been replicated in both a healthy control sample (n¼ 30) and an
MDD patient sample (n¼ 33), where stimulation led only to HR
decelerations at the F3/F4 and FC3/FC4 sites in both cohorts
(healthy controls: F3-C3: ES¼.463, FC3-C3: ES¼0.487). Up to 6
additional locations were tested, expressing only opposite patterns
on the group level [94; unpublished data]. Another independent
replication was conducted in a sample of 20 healthy subjects [95;
unpublished data].
Individual participant data meta-analysis
In order to objectively test and extend this NCG-TMS approach,
an individual participant data meta-analysis was conducted. Here
we aimed to 1) increase the power and, 2) to asses laterality dif-
ferences. Four cohorts were included: the individual data from the
original pilot study [85] and the 3 replication cohorts [94,95; un-
published data]. This resulted in a total of 99 NCG measurements
from 89 subjects (since subjects from the pilot study were tested
with both the left-sided and right-sided NCG-TMS), resulting in 41
NCG measurements obtained at the left hemisphere and 58 from
the right hemisphere. However, the C3 or C4 location was not
included in every cohort (not in the MDD cohort), leaving a total of
66 measurements in only healthy controls (41 on the left and 25 on
the right hemisphere) for F3/4-C3/4 and FC3/4-C3-4 comparisons.
Earlier calculations for sample size (GPower 3.1.9.2) indicated that
at least 22 subjects per hemisphere group were required to repli-
cate the results from the pilot study for both hemispheres [94;
unpublished data], indicating adequate power. It was hypothesized
that heart rate deceleration following stimulation at F3/4 would be
statistically different from C3/4, as indicated by the single studies,
and that there would be no effect of hemisphere. Since all studies
were conducted in the same manner, we pooled the data as if one
mega-trial, as a one-stage analysis [86]. Repeated measures ANOVA
was conducted with location as within-subjects factor and hemi-
sphere as between-subjects factor. To control for differences in
dataset, post-hoc analyses with dataset added as between-subjects
factor was conducted.
All datawere investigated for normality. See Fig. 3 for results. No
differences between left and right-sided stimulationwere found on
the amount of HR deceleration (F(1)¼0.837, p¼ 0.364), nor an
interaction of hemisphere with stimulation location (F(1.715)¼
0.640, p¼ .506). A main effect of location was found
Fig. 2. Example of the NCG-TMS method.
This figure shows an example of the NCG-TMS method, in where heart rate is recorded during stimulation on different cortical locations, with TMS. Here, 3 locations are being
stimulated (respectively FC4, C4 and F4; gray blocks on the x-axis), with 10HZ TMS, lasting 5 s per location. Plotted on the y-axis are the intervals between two consecutive r-peaks,
as recorded by ECG. During stimulation on F4, lengthening of the RR intervals is observed, showing heart rate deceleration.
cord; INS: insula; LC: locus coeruleus; BF: basal forebrain; NTS: nucleus of the solitary tract; OFC: orbitofrontal cortex; PAG: periaqueductal gray; PBN: parabrachial nucluei; PFC:
prefrontal cortex; PGi: nucleus paragigantocellularis; rACC: rostral anterior cingulate cortex; RVLM: rostral ventrolateral medulla; VMPFC: ventromedial prefrontal cortex; VN:
vagus nerve. Note: adapted from Ellis & Thayer, (2010). Brain graphic (https://commons.wikimedia.org/wiki/File:Brain_human _sagittal_section.svg; Patrick J. Lynch, medical
illustrator; Creative Commons Attribution 2.5 License 2006).
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(F(1.715)¼ 7.374, p¼ 0.002), as hypothesized. This main effect was
due to a significant difference between F3/4 and C3/4
(t(65)¼ 3.515, p¼ 0.001, Cohens D¼0.56) and FC3/4 and C3/4
(t(65)¼ 2.916, p¼ .005, Cohens D¼.47). No differences were found
between F3/4 and FC3/4 (t(65)¼ 1.774, p¼ 0.081). Post-hoc anal-
ysis with dataset as between-subjects factor indicated no differ-
ences between datasets (F(2)¼0.932, p¼ 0.399).
General discussion
We outlined a frontal-vagal brain-heart network that involves
direct autonomic connections to the heart for both the SNS and the
PNS from the first relay station of the CNS, showing overlap with
several key nodes in depression, highlighted by various neuro-
modulation treatments aimed at these nodes. It has been shown
that neuromodulation aimed at the DLPFC and the VN, directly
influences this network by decreasing HR or increasing HRV, but it
remains unclear what the effect of stimulation at the sgACC is.
Interestingly, this framework for MDD is applicable to alterna-
tive treatments for depression as well, such as meditation,
improving sleep quality, exercise, etc. These therapies have direct
influences on autonomic functions such as HR and breathing, thus
showing that the different therapies each exert their effect on
different levels of the same network. This could imply that
combining different treatments might be beneficial for treatment
response, as was found for the combination of rTMS with psycho-
therapy [78] where psychotherapy specifically activates the sgACC
[87] and thus works synergistically with the DLPFC rTMS stimula-
tion. With regard to antidepressant treatment, the exact working
mechanism is unclear, but a review and meta-analysis by Kemp
et al. [19] investigating the effects of antidepressants on cardiac
autonomic activity indicated that tricyclic antidepressants decrease
HRV, and that SSRIs have no effect on HRV. A study by Olbrich et al.
showed that the antidepressant effects of SNRIs was accompanied
by higher ANS arousal (e.g. HR) [88]. These findings show that
antidepressant medication shares overlap with the heart-brain
network as well, but the mechanism and direction of these treat-
ments remain unsettled. This emphasizes also a possible limitation
of the NCG-TMS method, since to date, no control for medication
use was included in the MDD patient cohort. Future research
should focus on the specific influences of antidepressant medica-
tion on NCG-TMS outcomes, as well as a focus on other drugs with a
specific cardiac effect, for example, beta-blockers and antipsy-
chotics, which are frequently used among MDD patients. Further-
more, substances such as nicotine or coffee may also confound
NCG-TMS results.
We stated that autonomic functioning is disturbed in MDD
(higher HR, lower HRV) by means of a shift between sympathetic
and parasympathetic activity. This could be a result of either
increased sympathetic activity, a decrease in parasympathetic ac-
tivity or both, but the exact mechanism is still unclear. Also, it has
yet to be determined whether high HR and low HRV are state or
trait related, and thus, will normalize with response to treatment.
Previous research suggests that an increase in HRV was related to
successful pharmacological treatment [89,90], and also with
acupuncture treatment [91] for depression. However, Udupa et al.
[80], did not find significant correlations between clinical
improvement and autonomic function parameters, for SSRI and
rTMS treatment and Brunoni et al., states that HRV is a trait marker
of MDD [92], not a state marker. Recently, a study using iTBS also
showed no differences over time for HR and several HRV indices as
a function of iTBS treatment [96]. Differences between responders
and non-responders in terms of HR and HRV have not been
investigated to a great extent, although it was recently shown in a
small sample that HR and HRV were not related to HRSD
improvement [96].
As mentioned, multiple animal studies are available demon-
strating HR decelerations after stimulation of the ventral regions of
the ACC. However, there is no substantial evidence on the effect of
DBS on HR in human subjects, since only a few studies investigated
HR changes while stimulating the SCC/sgACC, albeit with relatively
low stimulation intensities, relative to non-human studies
[69,71,76]. It also remains unclear how the findings from Fox et al.
[12], that showed an association between high DLPFC-sgACC anti-
correlation and better treatment outcome, relate to the DBS find-
ings, given that the DLPFC is associated with HR decreases. One
difference is that the Fox ‘method’makes use of a group sgACC seed
region, while with DBS electrode placement is performed individ-
ually according to structural MRI's, and subjective impressions of
the participant and there might be some discrepancy between both
locations. This may explain why HR decelerations were found with
TMS but not DBS, although both methods are similarly associated
with MDD symptom improvement.
This review emphasized the opportunities of using HR and HRV
metrics as a reliable marker of targeting the frontal-vagal depres-
sion network such as Neuro-Cardiac-Guided TMS, where the target
is localized using HR. This method has been successfully replicated
in 4 different samples, thereby the proof-of-concept has been
validated. However, thus far only preliminary evidence for an as-
sociation between the amount of HR-deceleration after a first ses-
sion of iTBS and a better clinical response has been reported [96],
therefore the relation to treatment outcome still needs to be
assessed more thoroughly. Furthermore, the individual participant
data meta-analysis indicated no differences between stimulation of
the left or right hemisphere, although earlier studies suggest
greater right prefrontal influence over vagal mediated cardiac
output. Still, it was also found that both prefrontal cortices are
linked to parasympathetic (vagal) activity [93], which is also sup-
ported by the individual participant data meta-analysis. It has to be
noted that gender differences have not yet been investigated for
NCG-TMS application. As mentioned earlier, gender differences
have been found for MDD, and HRV [36,42], indicating it is not
unlikely that men and women respond differently to NCG-TMS,
which would be a topic of interest for future research.
Fig. 3. Results from the individual participant meta-analysis, pooling the results from
4 studies.
RR interval lengthening (z-scores) during stimulation at different 10e20 system scalp
locations (F3/4, FC3/4, C3/4), either at the left hemisphere (in blue) or the right
hemisphere (in green). Increasing RR intervals represent lengthening of the interval,
thus, a decrease in HR. Note that no effect of laterality was found, only an effect of
location. Error bars represent standard errors of the mean (SEM). (For interpretation of
the references to colour in this figure legend, the reader is referred to the Web version
of this article.)
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Since the VN is involved in all parasympathetic functions,
stimulation of the DLPFC, sgACC or VN might also impact pupil
dilation and gastrointestinal function. Thus, these might also be
dysregulated in depression, and may also serve as markers of tar-
geting the depression network, but, the adequacy and utility of
these have yet to be established. Furthermore, the focus of this
review was on MDD, but could be translated to other psychiatric
disorders that impact the autonomic nervous system as well.
Conclusion
To summarize, autonomic functioning, such as HR and HRV,
could serve as potential target engagement mechanism for opti-
mizing and individualizing neuromodulation treatments in
depression. Based on this, we emphasize the importance of
including HR and HRV measurements during human depression
studies, in particular those that conduct neuromodulation, to
investigate to a better extent the acute effects of neuromodulation
on autonomic functioning, and to establish the efficacy of ECG
metrics in target engagement of the frontal-vagal network.
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